Holen Sie sich die Stockscreener-App
0.00
100.00%
-4.85
Schlusskurs vom Vortag:
$4.85
Offen:
$0
24-Stunden-Volumen:
0
Relative Volume:
0.00
Marktkapitalisierung:
$242.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
0.00
EPS:
-0.7341
Netto-Cashflow:
-
1W Leistung:
-100.00%
1M Leistung:
-100.00%
6M Leistung:
-100.00%
1J Leistung:
-100.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$0.00
$0.00
52-Wochen-Spanne:
$0.00
$4.9292
Genfit Adr Stock (GNFT) Company Profile
Compare GNFT vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GNFT
Genfit Adr
|
0.00 | 242.51M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
444.53 | 113.62B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
757.25 | 82.17B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
753.90 | 46.12B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
320.94 | 43.60B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
161.28 | 35.54B | 606.42M | -1.28B | -997.58M | -6.403 |
Genfit Adr Stock (GNFT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-19 | Fortgesetzt | H.C. Wainwright | Buy |
| 2021-12-20 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-07-23 | Hochstufung | Stifel | Hold → Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Underperform |
| 2020-05-13 | Herabstufung | Kepler | Buy → Reduce |
| 2020-05-12 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2020-05-12 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2019-10-29 | Bestätigt | B. Riley FBR | Buy |
| 2019-06-25 | Eingeleitet | Stifel | Hold |
| 2019-04-24 | Eingeleitet | SVB Leerink | Outperform |
| 2019-04-22 | Eingeleitet | Barclays | Overweight |
Alle ansehen
Genfit Adr Aktie (GNFT) Neueste Nachrichten
GENFIT signe un partenariat de recherche avec EVerZom pour faire progresser une technologie de médecine régénérative basée sur les exosomes dans l’ACLF - GlobeNewswire Inc.
GENFIT to Delist from Nasdaq, Focuses on Euronext Paris - TipRanks
European ADRs Start The Week With Small Gains Stateside - Finimize
FY2025 Earnings Estimate for GENFIT Issued By HC Wainwright - Defense World
HC Wainwright Has Pessimistic View of GENFIT FY2025 Earnings - MarketBeat
GENFIT (NASDAQ:GNFT) Price Target Lowered to $7.00 at HC Wainwright - Defense World
HC Wainwright Has Lowered Expectations for GENFIT (NASDAQ:GNFT) Stock Price - MarketBeat
European ADRs Tick Up As Pharma And Telecom Lead Gains - Finimize
European ADRs Show Optimism As Genfit Leads Gains - Finimize
European ADRs Show Strength With Genfit And Novo Nordisk Leading Gains - Finimize
symbol__ Stock Quote Price and Forecast - CNN
Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease - Ipsen
Ipsen and GENFIT Enter Into Exclusive Licensing Agreement for Elafibranor, a Phase III Asset Evaluated in Primary Biliary Cholangitis, as Part of a Long-Term Global Partnership - Business Wire
GNFT Stock Price and Chart — EURONEXT:GNFT - TradingView
The Daily Biotech Pulse: ChemoCentryx Triples On Data Readout, Global Blood Given FDA Nod, Positive Safety Review For Genfit's NASH Drug - Yahoo Finance
Should I buy GENFIT (GNFT) - Zacks Investment Research
GNFT: GENFITFull Company Report - Zacks Investment Research
GNFT Stock Price | Genfit S.A. ADR Stock Quote (U.S.: Nasdaq) - MarketWatch
Finanzdaten der Genfit Adr-Aktie (GNFT)
Es liegen keine Finanzdaten für Genfit Adr (GNFT) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.34%
0.05%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):